43 results on '"Lam, Sze-Kwan"'
Search Results
2. Contactin 1 modulates pegylated arginase resistance in small cell lung cancer through induction of epithelial–mesenchymal transition
- Author
-
Xu, Shi, Lam, Sze-Kwan, Cheng, Paul Ning-Man, and Ho, James Chung-Man
- Published
- 2019
- Full Text
- View/download PDF
3. Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma
- Author
-
Lam, Sze-Kwan, Yan, Sheng, Xu, Shi, U, Kin-Pong, Cheng, Paul Ning-Man, and Ho, James Chung-Man
- Published
- 2019
- Full Text
- View/download PDF
4. Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy.
- Author
-
Ko, Frankie Chi Fat, Yan, Sheng, Lee, Ka Wai, Lam, Sze Kwan, and Ho, James Chung Man
- Subjects
GALECTINS ,CYTOTOXIC T cells ,REGULATORY T cells ,T cells ,T-cell exhaustion ,IMMUNE checkpoint inhibitors ,NEUTROPHILS - Abstract
In humans, a total of 12 galectins have been identified. Their intracellular and extracellular biological functions are explored and discussed in this review. These galectins play important roles in controlling immune responses within the tumour microenvironment (TME) and the infiltration of immune cells, including different subsets of T cells, macrophages, and neutrophils, to fight against cancer cells. However, these infiltrating cells also have repair roles and are hijacked by cancer cells for pro-tumorigenic activities. Upon a better understanding of the immunomodulating functions of galectin-3 and -9, their inhibitors, namely, GB1211 and LYT-200, have been selected as candidates for clinical trials. The use of these galectin inhibitors as combined treatments with current immune checkpoint inhibitors (ICIs) is also undergoing clinical trial investigations. Through their network of binding partners, inhibition of galectin have broad downstream effects acting on CD8
+ cytotoxic T cells, regulatory T cells (Tregs), Natural Killer (NK) cells, and macrophages as well as playing pro-inflammatory roles, inhibiting T-cell exhaustion to support the fight against cancer cells. Other galectin members are also included in this review to provide insight into potential candidates for future treatment(s). The pitfalls and limitations of using galectins and their inhibitors are also discussed to cognise their clinical application. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. First report of an anti-tumor, anti-fungal, anti-yeast and anti-bacterial hemolysin from Albizia lebbeck seeds
- Author
-
Lam, Sze Kwan and Ng, Tzi Bun
- Published
- 2011
- Full Text
- View/download PDF
6. Antifungal and antiviral products of marine organisms
- Author
-
Cheung, Randy Chi Fai, Wong, Jack Ho, Pan, Wen Liang, Chan, Yau Sang, Yin, Cui Ming, Dan, Xiu Li, Wang, He Xiang, Fang, Evandro Fei, Lam, Sze Kwan, Ngai, Patrick Hung Kui, Xia, Li Xin, Liu, Fang, Ye, Xiu Yun, Zhang, Guo Qing, Liu, Qing Hong, Sha, Ou, Lin, Peng, Ki, Chan, Bekhit, Adnan A, Bekhit, Alaa El-Din, Wan, David Chi Cheong, Ye, Xiu Juan, Xia, Jiang, and Ng, Tzi Bun
- Published
- 2014
- Full Text
- View/download PDF
7. A protein with antiproliferative, antifungal and HIV-1 reverse transcriptase inhibitory activities from caper ( Capparis spinosa) seeds
- Author
-
Lam, Sze-Kwan and Ng, Tzi-Bun
- Published
- 2009
- Full Text
- View/download PDF
8. Purification and Characterization of an Antifungal Peptide with Potent Antifungal Activity but Devoid of Antiproliferative and HIV Reverse Transcriptase Activities from Legumi Secchi Beans
- Author
-
Lam, Sze Kwan and Ng, Tzi Bun
- Published
- 2013
- Full Text
- View/download PDF
9. Lectins: production and practical applications
- Author
-
Lam, Sze Kwan and Ng, Tzi Bun
- Published
- 2011
- Full Text
- View/download PDF
10. Salvage Therapy beyond Targeted Therapy in Lung Adenocarcinoma
- Author
-
Ho, James Chung-man, Tam, Terence Chi-chun, and Lam, Sze-kwan
- Published
- 2013
- Full Text
- View/download PDF
11. Editorial: Novel agents and combinations for treatment of malignant pleural mesothelioma in pre-clinical models.
- Author
-
Lam, Sze-Kwan and Mutsaers, Steven Eugene
- Subjects
ANIMAL models in research ,MESOTHELIOMA - Published
- 2022
- Full Text
- View/download PDF
12. Targeting polyamine as a novel therapy in xenograft models of malignant pleural mesothelioma.
- Author
-
Lam, Sze-Kwan, Yan, Sheng, Xu, Shi, and Ho, James Chung-Man
- Subjects
- *
ORNITHINE decarboxylase , *PLEURA cancer , *TREATMENT effectiveness , *POLYAMINES , *DNA damage , *THERAPEUTICS , *APOPTOSIS - Abstract
• Anticancer effects of DFMO in MPM xenografts. • Spermidine depletion, peroxynitrite elevation, inhibition of actin polymerization. • Activation of apoptosis. • Outstanding extended adjuvant treatment effect in the epithelioid mesothelioma model. Inhalation of asbestos fibers is the key culprit in malignant pleural mesothelioma (MPM). Although the import and use of asbestos have been restricted, the incidence of MPM continues to increase globally due to the prolonged lag time in malignant transformation. The development of a novel adjuvant therapy for the minority of individuals with resectable early-stage disease and effective treatment for those with unresectable MPM are urgently needed. Our preliminary data revealed that ornithine decarboxylase (ODC) is highly expressed in MPM xenografts. This study aimed to determine the treatment effects of α-difluoromethylornithine (DFMO), a specific ODC inhibitor, in MPM xenografts. In an "extended adjuvant DFMO treatment" setting, nude mice were fed with DFMO for 7 days prior to inoculation of 200,000 cells. DFMO suppressed tumor growth and increased median survival in both xenografts. In H226 xenograft, 43 % of treated mice had not reached the humane endpoint by day 132, mimicking long-term survival. DFMO decreased spermidine, increased nitrotyrosine and activated apoptosis in both xenografts. Furthermore, increase in nitrosocysteine, intratumoral IL-6, keratinocyte chemoattractant and TNFα, DNA lesion and inhibition of the Akt/mTOR pathway were induced by DFMO in H226 xenograft. In "DFMO treatment" setting, 107 cells were inoculated into nude mice and DFMO treatment commenced when tumor size reached ∼50−100 mm3. DFMO also suppressed tumor growth by similar mechanisms. Supplementation with spermidine reversed the therapeutic effect of DFMO. DFMO increased actin nitration at tyrosine 53 and inhibited actin polymerization. DFMO is preclinically effective in treating MPM. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer.
- Author
-
Xu, Shi, Lam, Sze‐Kwan, Cheng, Paul Ning‐Man, and Ho, James Chung‐Man
- Abstract
Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer cases. Small cell lung cancer is characterized by frequent relapse, and current treatments lack tumor specificity. Arginine is a non‐essential amino acid for human normal cells but critical to some tumor cells that cannot synthesize arginine. Therefore, arginine deprivation has become a potential therapeutic option for selected tumors. BCT‐100 is a pegylated arginase that has documented anticancer activity in arginine auxotrophic tumors, such as melanoma, hepatocellular carcinoma, and acute myeloid leukemia. One of the resistance mechanisms to arginase treatment is overexpression of argininosuccinate synthetase (ASS1) and ornithine transcarbamylase (OTC), two important enzymes in the urea cycle. We selected 9 SCLC and 1 non‐small cell lung carcinoma cell lines to determine the growth inhibition effects of BCT‐100 and established that cell lines with low expression of ASS1 and OTC are relatively sensitive to BCT‐100 treatment. Knocking down OTC in a H841 cell line could potentiate its sensitivity to BCT‐100 treatment. Arginine concentration was sharply decreased, accompanied by apoptosis through oxidative stress as well as G1 cell cycle arrest. In addition, BCT‐100 showed an anticancer effect on H446 and H510A xenograft models by lowering arginine levels and inducing apoptosis. BCT‐100 is one type of pegylated recombinant human arginase. BCT‐100 showed an anticancer effect against small cell lung cancer through oxidative stress, apoptosis, and cell cycle arrest. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models.
- Author
-
Lam, Sze-Kwan, Pong U, Kin, Li, Yuan-Yuan, Xu, Shi, Cheng, Paul Ning-Man, and Ho, James Chung-Man
- Published
- 2018
- Full Text
- View/download PDF
15. P3.03-018 Suppression of Tumor Growth by Pegylated Arginase in Malignant Pleural Mesothelioma: Topic: Mesothelioma Transitional
- Author
-
Chung-Man Ho, James, U, Kin-Pong, Xu, Shi, Ning-Man Cheng, Paul, and Lam, Sze Kwan
- Published
- 2017
- Full Text
- View/download PDF
16. P3.01-043 Inhibition of Ornithine Decarboxylase Facilitates Pegylated Arginase Treatment in Lung Adenocarcinoma Xenograft Models: Topic: Functional Biology in Lung Cancer
- Author
-
Chung-Man Ho, James, Kin-Pong, U., Xu, Shi, Ning-Man Cheng, Paul, and Lam, Sze Kwan
- Published
- 2017
- Full Text
- View/download PDF
17. P1.07-029 In Vitro Effects of Pegylated Arginase in Small Cell Lung Cancer: Topic: Molecular Changes
- Author
-
Xu, Shi, Lam, Sze Kwan, Man Cheng, Paul Ning, and Man Ho, James Chung
- Published
- 2017
- Full Text
- View/download PDF
18. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
- Author
-
Sze-Kwan Lam, Yuan-Yuan Li, Shi Xu, Lee Leung, Leanne, Kin-Pong U, Yan-Fang Zheng, Ning-Man Cheng, Paul, Chung-Man Ho, James, Lam, Sze-Kwan, Li, Yuan-Yuan, Xu, Shi, Leung, Leanne Lee, U, Kin-Pong, Zheng, Yan-Fang, Cheng, Paul Ning-Man, and Ho, James Chung-Man
- Subjects
TUMOR suppressor proteins ,ARGINASE ,MESOTHELIOMA ,XENOGRAFTS ,LIVER cancer ,LABORATORY mice ,ANIMAL experimentation ,ANTINEOPLASTIC agents ,APOPTOSIS ,CELL lines ,CELL physiology ,DOSE-effect relationship in pharmacology ,HYDROLASES ,LUNG tumors ,MICE ,POLYETHYLENE glycol ,PLEURAL tumors ,TREATMENT effectiveness - Abstract
Background: Malignant pleural mesothelioma (MPM) is a difficult-to-treat global disease. Pegylated arginase (BCT-100) has recently shown anti-tumor effects in hepatocellular carcinoma, acute myeloid leukemia and melanoma. This study aims to investigate the effects of PEG-BCT-100 in MPM.Methods: A panel of 5 mesothelioma cell lines (H28, 211H, H226, H2052 and H2452) was used to study the in vitro effects of BCT-100 by crystal violet staining. The in vivo effects of BCT-100 were studied using 211H and H226 nude mice xenografts. Protein expression (argininosuccinate synthetase, ornithine transcarbamylase, cleaved PARP, cleaved caspase 3, cyclins (A2, D3, E1 and H), CDK4 and Ki67) and arginine concentration were evaluated by Western blot and ELISA respectively. Cellular localization of BCT-100 was detected by immunohistochemistry and immunoflorescence. TUNEL assay was used to identify cellular apoptotic events.Results: Argininosuccinate synthetase was expressed in H28, H226, and H2452 cells as well as 211H and H266 xenografts. Ornithine transcarbamylase was undetectable in all cell lines and xenograft models. BCT-100 reduced in vitro cell viability (IC50 values at 13-24 mU/ml, 72 h) across different cell lines and suppressed tumor growth in both 211H and H226 xenograft models. BCT-100 (60 mg/kg) significantly suppressed tumor growth (p < 0.01) with prolonged median survival (p < 0.01) in both xenograft models. Combining BCT-100 with pemetrexed or cisplatin conferred no additional benefits over single agents. Serum and intratumoral arginine levels were effectively decreased by BCT-100, associated with cytosolic accumulation of BCT-100 within tumor cells. Apoptosis (PARP cleavage in 211H xenografts; Bcl-2 downregulation, and cleavage of PARP and caspase 3 in H226 xenografts; positive TUNEL staining in both) and G1 arrest (downregulation of cyclin A2, D3, E1 and CDK4 in 211H xenografts; suppression of cyclin A2, E1, H and CDK4 in H226 xenografts) were evident with BCT-100 treatment. Furthermore, proliferative factor Ki67 was downregulated in BCT-100 treatments arms.Conclusions: BCT-100 suppressed tumor growth with prolonged median survival partially mediated by intratumoral arginine depletion resulting in apoptosis and G1 arrest in mesothelioma xenograft models. The findings provide scientific evidence to support further clinical development of BCT-100 in treatment of MPM. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
19. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
- Author
-
Lam, Sze-Kwan, Leung, Leanne Lee, Li, Yuan-Yuan, Zheng, Chun-Yan, and Ho, James Chung-Man
- Subjects
- *
ARSENIC trioxide , *FIBROBLAST growth factor receptors , *LUNG cancer treatment , *CARCINOMA , *HUMAN cell cycle , *PHOSPHATIDYLSERINES , *MITOCHONDRIAL membranes , *THERAPEUTICS - Abstract
Objectives Lung cancer remains the top cancer killer worldwide, with squamous cell carcinoma (SCC) as the second commonest histologic subtype. Arsenic trioxide (ATO) was previously shown to suppress growth of lung cancer. Fibroblast growth factor receptor (FGFR) amplification was recently demonstrated in lung SCC, with specific FGFR inhibitor (e.g. PD173074) developed as a potential targeted therapy. Therefore the combination effects of ATO and PD173074 in SCC was studied. Materials and methods The combination of ATO/PD173074 was studied in a proof-of-principle model using a lung SCC cell line with FGFR1 overexpression: SK-MES-1. The effects of ATO and/or PD173074 on cell viability and protein expression were studied by MTT assay and Western blot respectively. Cell cycle analysis, phosphatidylserine externalization and mitochondrial membrane depolarization were monitored by flow cytometry. FGFR1 knockdown was performed with siRNAs. Proteasome inhibitor (MG-132) was used to study the degradation mechanism. In vivo effect of ATO and/or PD173074 was investigated using a nude mice xenograft model. Results Combined ATO/PD173074 reduced cell viability along with increased sub-G1 population, phosphatidylserine externalization and mitochondrial membrane depolarization more significantly than single treatments. Downregulation of FGFR1, p-Akt, Akt, p-Src, Src, p-c-Raf, c-Raf, Erk and survivin as well as upregulation of p-Erk and cleaved PARP were observed upon ATO and/or PD treatment. MG-132 partially reversed the degradation of Akt, Src, c-Raf and Erk induced by ATO/PD, suggestive of ubiquitin-independent proteasome-dependent degradation. However, the mechanism of FGFR1 downregulation remained unknown. Downregulation of FGFR1, Akt, Src, c-Raf and Erk as well as cleaved PARP elevation induced by ATO and/or PD were confirmed in vivo . Conclusion Massive protein degradation (FGFR1, Akt, Src, c-Raf and Erk) was induced by ATO and/or PD173074 treatment mainly mediated by activation of proteasomal degradation in SCC cell line SK-MES-1 in vitro and in vivo . [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. Combination of Arginine Depletion and Chemotherapy in Thoracic Malignancies.
- Author
-
James Chung-Man Ho, Sze-Kwan Lam, Ho, James Chung-Man, and Lam, Sze-Kwan
- Published
- 2017
- Full Text
- View/download PDF
21. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
- Author
-
Zheng, Chun-yan, Lam, Sze-kwan, Li, Yuan-yuan, Fong, Bonnie Mei-wah, Mak, Judith Choi-wo, and Ho, James Chung-man
- Subjects
- *
CANCER treatment , *SMALL cell lung cancer , *ARSENIC trioxide , *CANCER chemotherapy , *COMBINATION drug therapy , *CANCER-related mortality , *DRUG efficacy , *LEUKEMIA treatment , *IN vitro studies , *THERAPEUTICS - Abstract
Abstract: Introduction: Small cell lung cancer (SCLC) carries high mortality despite standard chemotherapy. Arsenic trioxide (ATO) has demonstrated clinical efficacy in leukemia and in vitro activity in various solid tumors. This study was conducted to determine the in vitro and in vivo combination effects of ATO and chemotherapy in SCLC. Materials and methods: The in vitro model consisted of 5 SCLC cell lines (H187, H526, H69, H841 and DMS79) and the anti-proliferative effects of ATO, cisplatin, etoposide or combinations thereof were measured. Synergism was determined by calculation of the combination index (CI) according to Chou and Talalay. Assays for apoptosis, intracellular glutathione (GSH) content, and mitochondrial membrane depolarization (MMD) were performed. Arsenic content was measured by inductively coupled plasma-mass spectrometry. Expression level of MRP1, MRP2 and pH2AX was detected by Western blot while cellular pH2AX level was monitored by immunofluorescent staining. An in vivo xenograft model in nude mice was established with a H841 cell line to test the effects of drug combinations. Results: All 5 SCLC cell lines were sensitive to ATO, with IC50 values (48h) 1.6–8μM. Synergistic or additive effects were obtained by combining cisplatin with ATO in all 5 cell lines. Combination of etoposide with ATO resulted in antagonistic or barely additive effects. Apoptotic assays and pH2AX immunofluorescent staining corroborated the synergistic combination of ATO and cisplatin. In addition, the ATO/cisplatin combination enhanced MMD, depleted GSH, downregulated MRP2 and elevated intracellular ATO content compared with either ATO or cisplatin alone. In vivo combination of ATO and cisplatin also demonstrated synergism in the H841 xenograft model. Conclusions: There was clinically relevant in vitro activity of ATO in a panel of 5 SCLC cell lines. Significant synergism was demonstrated with the ATO/cisplatin combination, while antagonism was noted with the ATO/etoposide combination in both in vitro and in vivo models. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
22. Personalized Treatment of Lung Adenocarcinoma.
- Author
-
Ho, James Chung-Man, Tam, Terence Chi-Chun, and Lam, Sze-Kwan
- Published
- 2013
- Full Text
- View/download PDF
23. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
- Author
-
Li, Yuan-yuan, Lam, Sze-kwan, Mak, Judith Choi-wo, Zheng, Chun-yan, and Ho, James Chung-man
- Subjects
- *
EPIDERMAL growth factor receptors , *LUNG cancer treatment , *PROTEIN-tyrosine kinase inhibitors , *AUTOPHAGY , *GENETIC mutation , *CANCER cells , *RNA interference - Abstract
Abstract: Purpose: Erlotinib is a commonly used tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). Autophagy is a catabolic process in response to stress and deprivation of nutrients. This study aims to investigate whether autophagy confers acquired resistance to erlotinib treatment in NSCLC. Methods: Four NSCLC cell lines (HCC827, HCC4006, H358 and H1975) with different epidermal growth factor receptor (EGFR) mutation status (exon 19 deletion, exon 19 deletion, wild-type and L858R/T790M respectively) were selected. MTT assay, crystal violet staining and Annexin-V assay were performed to determine cell viability and apoptosis. Autophagic proteins were detected by Western blot. Acidic vesicular organelle (AVO) formation was determined by acridine orange staining. Autophagy inhibitor (chloroquine) and RNA interference were used to demonstrate the biological effect of erlotinib-induced autophagy. Results: In line with EGFR mutation status, it was shown that both HCC827 and HCC4006 cells were sensitive to erlotinib, while H358 and H1975 cell lines were resistant. Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression. Addition of chloroquine, as an autophagy inhibitor, enhanced erlotinib sensitivity in sensitive cells. Similarly, silencing of Atg5 or Beclin-1 significantly increased sensitivity to erlotinib in both sensitive cell lines. In contrast, there was no induction of autophagy in resistant H358 and H1975 cell lines upon erlotinib exposure. Conclusions: Erlotinib can induce both apoptosis and autophagy in sensitive NSCLC cell lines with activating EGFR mutation (exon 19 del). Inhibition of autophagy can further enhance sensitivity to erlotinib in EGFR-mutated NSCLC, suggesting that autophagy may serve as a protective mechanism. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
24. Apoptosis of human breast cancer cells induced by hemagglutinin from Phaseolus vulgaris cv. Legumi secchi
- Author
-
Lam, Sze Kwan and Ng, Tzi Bun
- Subjects
- *
BREAST cancer treatment , *APOPTOSIS , *CANCER cell proliferation , *HEMAGGLUTININ , *COMMON bean , *MOLECULAR weights , *REVERSE transcriptase , *MITOCHONDRIAL membranes , *AMINO acid sequence - Abstract
Abstract: A dimeric hemagglutinin with a relative molecular mass of 62000 was purified from seeds of Phaseolus vulgaris cultivar “Legumi secchi”. The chromatographic protocol included the use of Blue-Sepharose, Q-Sepharose, and Superdex 75. The N-terminal amino acid sequence of the hemagglutinin resembled those of other Phaseolus hemagglutinins. Its hemagglutinating activity was stable from 0°C to 60°C, and pH 4–11. It inhibited HIV-1 reverse transcriptase (IC50 of 17.3μM) and suppressed the proliferation of breast cancer MCF-7 cells (IC50 of 0.2μM). However, it was devoid of antifungal activity. The hemagglutinin-treated MCF-7 cells showed a number of changes, including cell cycle arrest in G2/M phase, phosphatidylserine externalisation and mitochondrial membrane depolarisation. The hemagglutinin-induced apoptosis through the death receptor-mediated pathway involved Fas ligands, caspase-8 activation, BID truncation, p53 release, caspase-9 activation and Lamin A/C truncation. The understanding of the apoptotic mechanism may be of value for application in tumor therapy. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
25. First report of an antifungal amidase from Peltophorum ptercoarpum.
- Author
-
Lam, Sze Kwan and Ng, Tzi Bun
- Abstract
A 60 kDa antifungal amidase was purified from Peltophorum ptercoarpum seeds using an isolation procedure that entailed ion-exchange chromatography on Q-Sepharose, ion-exchange chromatography on DEAE-cellulose and FPLC-gel filtration on Superdex 75. Unlike most other antifungal proteins isolated previously, it was adsorbed on Q-Sepharose and DEAE-cellulose. The isolated protein, designated as peltopterin, exhibited an N-terminal amino acid sequence closely resembling those of amidases. It exhibited amidase activity and digested iodoacetamide with an optimum pH and temperature at pH 9 and 50°C, respectively. It also hydrolyzed acrylamide and urea. It impeded mycelial growth in Rhizotonia solani with an IC
50 of 0.65 μ m. Chitin deposition at hyphal tips in R. solani was observed by staining with Congo red after incubation with peltopterin. Its antifungal activity was stable throughout pH 0-14 and 25-100°C. It potently inhibited HIV-1 reverse transcriptase with an IC50 of 27 n m. Copyright © 2009 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
26. Erratum: First report of an antifungal amidase from Peltophorum ptercoarpum.
- Author
-
Lam, Sze Kwan and Ng, Tzi Bun
- Published
- 2010
- Full Text
- View/download PDF
27. Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.
- Author
-
Han, Li, Lee, Cheuk-Kwong, Pang, Herbert, Chan, Hong-Tou, Lo, Iek-Long, Lam, Sze-Kwan, Cheong, Tak-Hong, and Ho, James Chung-Man
- Subjects
- *
ADENOCARCINOMA , *SINGLE nucleotide polymorphisms , *LUNG cancer , *GENETIC mutation , *CHINESE people , *EPIDERMAL growth factor receptors , *GENETICS , *DISEASES - Abstract
Objectives The inconsistent findings from genetic association studies may be related to the heterogeneity in different molecular subtypes of lung cancer. This study evaluated the predisposing single-nucleotide polymorphisms (SNPs) in epidermal growth factor receptor (EGFR) mutant and EGFR wild-type lung adenocarcinoma separately among never-smokers. Materials and methods This was a two-stage case-control study. Never-smokers with pathologically confirmed lung adenocarcinoma and healthy controls were recruited in Hong Kong and Macau. Genomic DNA was extracted and genotyped by MassARRAY. In the discovery stage, 51 SNPs were investigated at the SNP, gene and pathway level among 103 EGFR mutant and 78 EGFR wild-type lung adenocarcinoma cases compared with matched controls. In the validation stage, SNPs that were identified with significant lung cancer risk were replicated in a separate cohort of 84 lung adenocarcinoma cases and compared with 103 Chinese Han, Beijing and 105 Chinese Han, Southern public controls from the 1000 genome database. Results and conclusion The genetic association of IL-6 rs2069840 with EGFR mutant lung adenocarcinoma was ascertained. In the discovery stage, haplotype GGG in three SNPs (rs2069840, rs2069852, rs2066992) of IL-6, synergetic effects of IL-6 rs2069840 and environmental tobacco smoke in the workplace were found to be related to EGFR mutant lung adenocarcinoma. ERCC2 rs238406 showed a marginally significant association with EGFR mutant lung adenocarcinoma in the validation stage (P = 0.096). ERCC2 rs50871 and ATM rs611646 showed significant association with EGFR wild-type lung adenocarcinoma in the discovery stage. In conclusion, IL-6 rs2069840 conferred susceptibility to EGFR mutant lung adenocarcinoma in a Hong Kong and Macau never-smoking Chinese population. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. The anti-neoplastic impact of thymoquinone from Nigella sativa on small cell lung cancer: In vitro and in vivo investigations.
- Author
-
Khan M, Lam SK, Yan S, Feng Y, Chen C, Ko FC, and Ho JC
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Mice, Nude, Cell Cycle Checkpoints drug effects, Signal Transduction drug effects, Benzoquinones pharmacology, Benzoquinones therapeutic use, Nigella sativa chemistry, Small Cell Lung Carcinoma drug therapy, Small Cell Lung Carcinoma pathology, Xenograft Model Antitumor Assays, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Lung Neoplasms metabolism, Apoptosis drug effects, Reactive Oxygen Species metabolism
- Abstract
Purpose: Malignant and aggressive, small cell lung cancer (SCLC) constitutes about 15% of all diagnosed lung cancer cases. With primary therapeutic options such as chemotherapy accompanied by debilitating side effects, interest has been soaring in the therapeutic competencies of herbs. The pharmacological driving force behind the beneficial properties of Nigella sativa is the quinone, thymoquinone (TQ). The anti-cancer effects of TQ on different cancers have been extensively studied. Nonetheless, only one paper in the entire National Center for Biotechnology Information (NCBI) database describes its effects on SCLC. A more detailed investigation is required., Methods: The current study examined the impact of TQ in vitro on five SCLC cell lines and in vivo in a nude mouse xenograft model. The following in vitro effects of TQ on SCLC were evaluated: (a) cell viability; (b) apoptosis; (c) cell cycle arrest; (d) intracellular reactive oxygen species (ROS) levels, and (e) protein expression in concomitant signaling pathways. For the in vivo effects of TQ on SCLC, (a) tumor volume was measured, and (b) selected protein expression in selected concomitant signaling pathways was determined by Western blotting., Result: In general, TQ reduced cell viability, induced apoptosis and cell cycle arrest, depleted ROS, and altered protein expression in associated signaling pathways. Furthermore, TQ exhibited a tumor-suppressive effect in an H446 SCLC xenograft model., Conclusion: The cytotoxic impact of TQ arising from anti-cancer mechanisms was elucidated. The positive results obtained in this study warrant further investigation., (Copyright © 2024 Copyright: © 2024 Journal of Cancer Research and Therapeutics.)
- Published
- 2024
- Full Text
- View/download PDF
29. Disturbance of the Warburg effect by dichloroacetate and niclosamide suppresses the growth of different sub-types of malignant pleural mesothelioma in vitro and in vivo .
- Author
-
Lam SK, Yan S, Lam JS, Feng Y, Khan M, Chen C, Ko FC, and Ho JC
- Abstract
Background: Inhalation of asbestos fibers is the most common cause of malignant pleural mesothelioma (MPM). In 2004, the United States Food and Drug Administration approved a combination of cisplatin with pemetrexed to treat unresectable MPM. Nonetheless novel treatment is urgently needed. The objective of this study is to report the combination effect of dichloroacetate (DCA) or niclosamide (Nic) Nic in MPM. Materials and methods: The effect of a combination of DCA and Nic was studied using a panel of MPM cell lines (H28, MSTO-211H, H226, H2052, and H2452). Cell viability was monitored by MTT assay. Glycolysis, oxidative phosphorylation, glucose, glycogen, pyruvate, lactate, citrate, succinate and ATP levels were determined by corresponding ELISA. Apoptosis, mitochondrial transmembrane potential, cell cycle analysis, hydrogen peroxide and superoxide were investigated by flow cytometry. Cell migration and colony formation were investigated by transwell migration and colony formation assays respectively. The in vivo effect was confirmed using 211H and H226 nude mice xenograft models. Results and conclusion: Cell viability was reduced. Disturbance of glycolysis and/or oxidative phosphorylation resulted in downregulation of glycogen, citrate and succinate. DCA and/or Nic increased apoptosis, mitochondrial transmembrane depolarization, G2/M arrest and reactive oxygen species. Moreover, DCA and/or Nic suppressed cell migration and colony formation. Furthermore, a better initial tumor suppressive effect was induced by the DCA/Nic combination compared with either drug alone in both 211H and H226 xenograft models. In H226 xenografts, DCA/Nic increased median survival of mice compared with single treatment. Single drug and/or a combination disturbed the Warburg effect and activated apoptosis, and inhibition of migration and proliferation in vivo . In conclusion, dichloroacetate and/or niclosamide showed a tumor suppressive effect in MPM in vitro and in vivo, partially mediated by disturbance of glycolysis/oxidative phosphorylation, apoptosis, ROS production, G2/M arrest, and suppression of migration and proliferation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Lam, Yan, Lam, Feng, Khan, Chen, Ko and Ho.)
- Published
- 2022
- Full Text
- View/download PDF
30. Tumour growth-suppressive effect of arsenic trioxide in squamous cell lung carcinoma.
- Author
-
Leung LL, Lam SK, Li YY, and Ho JC
- Abstract
Lung squamous cell carcinoma (SCC) is the second most common subtype of non-small cell lung carcinoma. The anticancer effects of arsenic trioxide (ATO) in lung adenocarcinoma and small-cell lung cancer have previously been reported; however its effects in SCC remain unclear. An MTT assay and western blot analysis were performed to determine cell viability and protein expression, respectively, in the SK-MES-1 and SW900 SCC cell lines following treatment with ATO. Phosphatidylserine externalization, mitochondrial membrane depolarization and cell cycle distribution were studied using flow cytometry and the in vivo effects of ATO on tumour growth were investigated with a xenograft model. The results demonstrated that SK-MES-1 and SW900 SCC cells were sensitive to clinically relevant concentrations of ATO. ATO induced apoptosis, mitochondrial membrane depolarization and G
2 /M arrest. In addition, treatment with ATO resulted in the downregulation of X-linked inhibitor of apoptosis, B-cell lymphoma-2 (Bcl-2), E2F transcription factor 1 (E2F1), thymidylate synthase and ribonucleotide reductase M1 in addition to the upregulation of Bcl-2 antagonist/killer protein, cleaved poly ADP-ribose polymerase and cleaved caspase 3 in a cell-line specific manner. In the SW900 xenograft model, tumour growth was inhibited by ATO with the formation of apoptotic bodies and downregulation of Bcl-2 and E2F1. In conclusion, ATO suppresses the growth of SCC in vitro and in vivo .- Published
- 2017
- Full Text
- View/download PDF
31. Combination of Arginine Depletion and Chemotherapy in Thoracic Malignancies.
- Author
-
Ho JC and Lam SK
- Subjects
- Arginine, Argininosuccinate Synthase, Humans, Hydrolases, Pemetrexed, Polyethylene Glycols, Cisplatin, Thoracic Neoplasms
- Published
- 2017
- Full Text
- View/download PDF
32. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
- Author
-
Lam SK, Li YY, Xu S, Leung LL, U KP, Zheng YF, Cheng PN, and Ho JC
- Subjects
- Animals, Antineoplastic Agents administration & dosage, Cell Line, Tumor, Dose-Response Relationship, Drug, Female, Humans, Mesothelioma, Malignant, Mice, Mice, Inbred BALB C, Mice, Nude, Polyethylene Glycols chemistry, Treatment Outcome, Apoptosis drug effects, Arginase administration & dosage, Cell Proliferation drug effects, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Mesothelioma drug therapy, Mesothelioma pathology, Pleural Neoplasms drug therapy, Pleural Neoplasms pathology
- Abstract
Background: Malignant pleural mesothelioma (MPM) is a difficult-to-treat global disease. Pegylated arginase (BCT-100) has recently shown anti-tumor effects in hepatocellular carcinoma, acute myeloid leukemia and melanoma. This study aims to investigate the effects of PEG-BCT-100 in MPM., Methods: A panel of 5 mesothelioma cell lines (H28, 211H, H226, H2052 and H2452) was used to study the in vitro effects of BCT-100 by crystal violet staining. The in vivo effects of BCT-100 were studied using 211H and H226 nude mice xenografts. Protein expression (argininosuccinate synthetase, ornithine transcarbamylase, cleaved PARP, cleaved caspase 3, cyclins (A2, D3, E1 and H), CDK4 and Ki67) and arginine concentration were evaluated by Western blot and ELISA respectively. Cellular localization of BCT-100 was detected by immunohistochemistry and immunoflorescence. TUNEL assay was used to identify cellular apoptotic events., Results: Argininosuccinate synthetase was expressed in H28, H226, and H2452 cells as well as 211H and H266 xenografts. Ornithine transcarbamylase was undetectable in all cell lines and xenograft models. BCT-100 reduced in vitro cell viability (IC
50 values at 13-24 mU/ml, 72 h) across different cell lines and suppressed tumor growth in both 211H and H226 xenograft models. BCT-100 (60 mg/kg) significantly suppressed tumor growth (p < 0.01) with prolonged median survival (p < 0.01) in both xenograft models. Combining BCT-100 with pemetrexed or cisplatin conferred no additional benefits over single agents. Serum and intratumoral arginine levels were effectively decreased by BCT-100, associated with cytosolic accumulation of BCT-100 within tumor cells. Apoptosis (PARP cleavage in 211H xenografts; Bcl-2 downregulation, and cleavage of PARP and caspase 3 in H226 xenografts; positive TUNEL staining in both) and G1 arrest (downregulation of cyclin A2, D3, E1 and CDK4 in 211H xenografts; suppression of cyclin A2, E1, H and CDK4 in H226 xenografts) were evident with BCT-100 treatment. Furthermore, proliferative factor Ki67 was downregulated in BCT-100 treatments arms., Conclusions: BCT-100 suppressed tumor growth with prolonged median survival partially mediated by intratumoral arginine depletion resulting in apoptosis and G1 arrest in mesothelioma xenograft models. The findings provide scientific evidence to support further clinical development of BCT-100 in treatment of MPM.- Published
- 2017
- Full Text
- View/download PDF
33. Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity.
- Author
-
Zheng CY, Lam SK, Li YY, and Ho JC
- Subjects
- Antioxidants pharmacology, Apoptosis drug effects, Arsenic Trioxide, Butylated Hydroxyanisole pharmacology, Cell Death drug effects, Cell Line, Tumor drug effects, DNA Damage drug effects, Glutathione metabolism, Homeostasis drug effects, Humans, Lung Neoplasms metabolism, Lung Neoplasms pathology, Mitochondria metabolism, Oxidation-Reduction, Reactive Oxygen Species metabolism, Small Cell Lung Carcinoma metabolism, Small Cell Lung Carcinoma pathology, Thioredoxins metabolism, Antineoplastic Agents pharmacology, Arsenicals pharmacology, Lung Neoplasms drug therapy, Mitochondria drug effects, Oxides pharmacology, Small Cell Lung Carcinoma drug therapy
- Abstract
Arsenic trioxide (ATO) has demonstrated anticancer activity in different malignancies, especially acute promyelocytic leukemia, with a wide array of putative mechanisms. In this study, we aimed to elucidate the activity and mechanisms of ATO in small cell lung cancer (SCLC). A panel of SCLC cell lines (H841, DMS79, H526, H69 and H187) was employed to demonstrate the activity of ATO. Cell viability, apoptosis and mitochondrial membrane depolarization were assessed. Western blotting was performed to determine the alteration of pro-apoptotic and anti-apoptotic mediators. Reactive oxygen species (ROS) (hydrogen peroxide and superoxide) and intracellular glutathione (GSH) were measured. Antioxidants, N-acetyl-L-cysteine (NAC) and butylated hydroxyanisole (BHA), were applied to restore GSH content and reduce production of ROS. All SCLC cell lines were relatively sensitive to ATO with IC50 values below 10 µM. ATO induced cell death mainly through apoptosis in H841 cells in a dose-dependent manner. Hydrogen peroxide was the major ROS in SCLC cells induced by ATO. Along with GSH depletion and Bcl-2 downregulation, mitochondrial membrane permeabilization was enhanced, followed by release of AIF and SMAC from mitochondria to initiate different cell death pathways. NAC reversed cell death and molecular changes induced by ATO via restoring GSH and reducing ROS content. BHA inhibited hydrogen peroxide production completely and partially restored GSH content accounting for partial reversal of cell inhibition and mitochondrial dysfunction. Nonetheless, ATO reduced both reduced and oxidized form of thioredoxin 1 (Trx1) with no effect on Trx1 redox potential. ATO led to cell death in SCLC mainly through mitochondrial dysfunction, resulting from altered cellular redox homeostasis, namely, hydrogen peroxide generation, GSH depletion and Trx1 downregulation.
- Published
- 2015
- Full Text
- View/download PDF
34. The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma.
- Author
-
Li YY, Lam SK, Zheng CY, and Ho JC
- Abstract
Lung cancer is the top cancer killer worldwide. Tyrosine kinase inhibitors (TKIs), for example erlotinib, are commonly used to target epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (ADC). Autophagy is a cellular response to stress, serving as a protective mechanism during anticancer therapy. The tumor microenvironment (TME) is composed of non-tumor cells that include fibroblasts. Our study aimed to investigate the effect of TME on autophagy and TKI sensitivity. Following cell sorting after direct co-culturing, autophagy and cytokine production were observed in both HCC827 and MRC-5 cells. The synergistic combination of erlotinib and chloroquine (autophagy inhibitor) was observed under TME. Tumor growth was significantly suppressed with combined erlotinib/chloroquine compared with erlotinib in HCC827 xenografts.
- Published
- 2015
- Full Text
- View/download PDF
35. Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
- Author
-
Lam SK, Li YY, Zheng CY, and Ho JC
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Arsenic Trioxide, Arsenicals therapeutic use, Cell Line, Tumor, Down-Regulation drug effects, E2F1 Transcription Factor metabolism, Female, Gene Expression Regulation, Neoplastic drug effects, Humans, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Mesothelioma drug therapy, Mesothelioma pathology, Mesothelioma, Malignant, Mice, Mice, Inbred BALB C, Mice, Nude, Oxides therapeutic use, Thymidylate Synthase metabolism, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Arsenicals pharmacology, E2F1 Transcription Factor genetics, Lung Neoplasms genetics, Mesothelioma genetics, Oxides pharmacology, Thymidylate Synthase genetics
- Abstract
Malignant pleural mesothelioma is a global health issue. Arsenic trioxide (ATO) has been shown to suppress thymidylate synthase (TYMS) in lung adenocarcinoma and colorectal cancer, and induce apoptosis in acute promyelocytic leukemia. With TYMS as a putative therapeutic target, the effect of ATO in mesothelioma was therefore studied. A panel of 5 mesothelioma cell lines was used to study the effect of ATO on cell viability, protein expression, mRNA expression and TYMS activity by MTT assay, western blot, qPCR and tritium-release assay, respectively. The knockdown of TYMS and E2F1 was performed with a specific siRNA. Phosphatidylserine externalization and mitochondrial membrane depolarization were measured by Annexin V and JC-1 staining respectively. The in vivo effect of ATO was studied using a nude mouse xenograft model. Application of ATO demonstrated anticancer effects in the cell line model with clinically achievable concentrations. Downregulation of TYMS protein (except H226 cells and 1.25 µM ATO in H2052 cells) and mRNA expression (H28 cells), pRB1 (H28 cells) and E2F1 and TYMS activity (except H226 cells) were also evident. E2F1 knockdown decreased cell viability more significantly than TYMS knockdown. In general, thymidine kinase 1, ribonucleotide reductase M1, c-myc and skp2 were downregulated by ATO. p-c-Jun was downregulated in H28 cells while upregulated in 211H cells. Phosphatidylserine externalization, mitochondrial membrane depolarization, downregulation of Bcl-2 and Bcl-xL, and upregulation of Bak and cleaved caspase-3 were observed. In the H226 xenograft model, the relative tumor growth was aborted, and E2F1 was downregulated while cleaved caspase-3 was elevated and localized to the nucleus in the ATO treatment group. ATO has potent antiproliferative and cytotoxic effects in mesothelioma in vitro and in vivo, partially mediated through E2F1 targeting (less effect through TYMS targeting). There is sound scientific evidence to support the clinical application of ATO in treatment of mesothelioma.
- Published
- 2015
- Full Text
- View/download PDF
36. E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.
- Author
-
Lam SK, Li YY, Zheng CY, Leung LL, and Ho JC
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma pathology, Adenocarcinoma of Lung, Animals, Apoptosis drug effects, Arsenic Trioxide, Cell Line, Tumor, Cell Survival drug effects, Gene Expression Regulation, Neoplastic drug effects, Humans, Lung Neoplasms genetics, Lung Neoplasms pathology, Mice, United States, United States Food and Drug Administration, Xenograft Model Antitumor Assays, Adenocarcinoma drug therapy, Arsenicals administration & dosage, E2F1 Transcription Factor biosynthesis, Lung Neoplasms drug therapy, Oxides administration & dosage
- Abstract
Lung cancer is one of the most common cancers worldwide. Arsenic trioxide (ATO) has been approved by the US Food and Drug Administration for the treatment of acute promyelocytic leukemia. Nonetheless preliminary data have suggested potential activity of ATO in solid tumors including lung cancer. This study aimed to examine the underlying mechanisms of ATO in the treatment of lung adenocarcinoma. Using a panel of 7 lung adenocarcinoma cell lines, the effects of ATO treatment on cell viability, expression of E2F1 and its downstream targets, phosphatidylserine externalization, mitochondrial membrane depolarization and alteration of apoptotic/anti-apoptotic factors were studied. Tumor growth inhibition in vivo was investigated using a nude mouse xenograft model. ATO decreased cell viability with clinically achievable concentrations (8 µM) in all cell lines investigated. This was accompanied by reduced expression of E2F1, cyclin A2, skp2, c-myc, thymidine kinase and ribonucleotide reductase M1, while p-c-Jun was upregulated. Cell viability was significantly decreased with E2F1 knockdown. Treatment with ATO resulted in phosphatidylserine externalization in H23 cells and mitochondrial membrane depolarization in all cell lines, associated with truncation of Bid, downregulation of Bcl-2, upregulation of Bax and Bak, caspase-9 and -3 activation and PARP cleavage. Using the H358 xenograft model, the tumor growth was suppressed in the ATO treatment group during 8 days of treatment, associated with downregulation of E2F1 and upregulation of truncated Bid and cleaved caspase-3. In conclusion, ATO has potent in vitro and in vivo activity in lung adenocarcinoma, partially mediated through E2F1 downregulation and apoptosis.
- Published
- 2014
- Full Text
- View/download PDF
37. Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma.
- Author
-
Lam SK, Mak JC, Zheng CY, Li YY, Kwong YL, and Ho JC
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma of Lung, Animals, Antineoplastic Agents therapeutic use, Apoptosis drug effects, Arsenic Trioxide, Arsenicals therapeutic use, Cell Survival drug effects, Dose-Response Relationship, Drug, Female, Gene Expression Regulation, Neoplastic drug effects, Gene Knockdown Techniques, Humans, Liver Neoplasms, Experimental, Lung Neoplasms pathology, Mice, Mice, Nude, Oxides therapeutic use, Xenograft Model Antitumor Assays, Adenocarcinoma drug therapy, Antineoplastic Agents pharmacology, Arsenicals pharmacology, Lung Neoplasms drug therapy, Oxides pharmacology, Thymidylate Synthase genetics, Thymidylate Synthase metabolism
- Abstract
Thymidylate synthase (TYMS) is an important chemotherapeutic target in non-small cell lung cancer (NSCLC). Arsenic trioxide (ATO) has been shown to suppress TYMS in a colonic cancer model. We examined the effects of TYMS suppression by ATO in lung adenocarcinoma. A panel of 4 lung adenocarcinoma cell lines was used to determine the effects of ATO treatment on cell viability, TYMS expression (protein and mRNA), E2F1 protein expression and TYMS activity. TYMS knockdown and overexpression were performed. Tumor growth inhibition in vivo was studied using a nude mouse xenograft model. ATO showed antiproliferative effects with clinically achievable concentrations (around 1.1-6.9 µM) in 4 lung adenocarcinoma cell lines. Downregulation of TYMS protein and mRNA expression, reduced TYMS activity, and suppressed E2F1 expression were demonstrated in lung adenocarcinoma with ATO. Cell viability was reduced by 15-50% with TYMS knockdown. Overexpression of TYMS led to a 2.7-fold increase in IC50 value with ATO treatment in H358 cells, but not in H23 cells. Using a xenograft model with H358 cell line, relative tumor volume was reduced to 44% that of the control following 8 days of treatment with 7.5 mg/kg ATO, and associated with significant downregulation of TYMS protein expression. In conclusion, ATO has potent in vitro and in vivo activity in lung adenocarcinoma, and is partially mediated by transcriptional downregulation of TYMS.
- Published
- 2014
- Full Text
- View/download PDF
38. Pharmacotherapy approaches to antifungal prophylaxis.
- Author
-
Ng TB, Cheung RC, Ye Xj, Fang EF, Chan YS, Pan WL, Dan XL, Yin CM, Lam SK, Lin P, Ngai PH, Xia LX, Liu F, Ye XY, Wang HX, and Wong JH
- Subjects
- Azoles therapeutic use, Humans, Immunocompromised Host, Antifungal Agents therapeutic use, Mycoses prevention & control
- Abstract
Introduction: Invasive fungal infection (IFI) is a serious problem due to difficulties in early diagnosis and high mortality. Different approaches are adopted for the treatment and management of IFI, including prophylactic, empiric, preemptive and directed strategies., Areas Covered: This paper reviews the type of pharmacotherapy used for antifungal prophylaxis in infants with extremely low birth weights, pediatric patients with cardiac disease, preterm neonates, pediatric oncology patients, adult cancer patients with neutropenia, adult patients with hematologic malignancy, hematopoietic stem-cell transplantation recipients, organ transplant recipients, HIV-infected patients, immunosuppressed patients treated with moderate or high doses of corticosteroids, and patients with invasive fusariosis, candidemia, invasive candidiasis, systemic mycoses and immunocompromised patients., Expert Opinion: Azole drugs are the drugs most often used in cost-effective antifungal prophylaxis of patients with conditions such as immunodeficiency and cancer, which render them highly susceptible to IFI. Fluconazole is the most outstanding example. However, there are many azoles with different pharmacological characteristics that the physician can choose from. Echinocandins have favorable characteristics that make them useful for treating Candida infections. Antibodies, or their engineered derivatives directed against cell-wall polysaccharides and glycopeptides, and some protein epitopes of Candida albicans, appear to be a promising novel approach for prophylaxis against Candida infection and deserve further in-depth investigations.
- Published
- 2012
- Full Text
- View/download PDF
39. Acafusin, a dimeric antifungal protein from Acacia confusa seeds.
- Author
-
Lam SK and Ng TB
- Subjects
- Antifungal Agents isolation & purification, Antifungal Agents pharmacology, Cell Line, Tumor, Cell Proliferation drug effects, Chitin chemistry, Chitin metabolism, Chromatography, Liquid, Electrophoresis, Polyacrylamide Gel, HIV Reverse Transcriptase antagonists & inhibitors, Humans, Hydrogen-Ion Concentration, Hyphae chemistry, Hyphae metabolism, Plant Proteins isolation & purification, Plant Proteins metabolism, Plant Proteins pharmacology, Reverse Transcriptase Inhibitors, Rhizoctonia chemistry, Temperature, Acacia chemistry, Antifungal Agents chemistry, Plant Proteins chemistry, Seeds chemistry
- Abstract
A dimeric 34-kDa antifungal protein, designated as acafusin, was purified from Acacia confusa seeds using Q-Sepharose, DEAE-cellulose, Mono S and Superdex S75. It demonstrated antifungal activity toward Rhizoctonia solani with an IC(50) of 28 microM. Acafusin inhibited the activity of HIV-1 reverse transcriptase mildly with an IC(50) of 80 microM.
- Published
- 2010
- Full Text
- View/download PDF
40. First report of a haemagglutinin-induced apoptotic pathway in breast cancer cells.
- Author
-
Lam SK and Ng TB
- Subjects
- Cell Cycle drug effects, Cell Cycle physiology, Cell Line, Tumor, Cell Proliferation drug effects, Female, Humans, Phaseolus chemistry, Apoptosis drug effects, Breast Neoplasms metabolism, Breast Neoplasms pathology, Hemagglutinins pharmacology, Signal Transduction drug effects
- Abstract
A dimeric 64 kDa HA (haemagglutinin) was isolated with a high yield from dried Phaseolus vulgaris cultivar 'French bean number 35' seeds. It inhibited the proliferation of hepatoma HepG2 cells and breast cancer MCF-7 cells with an IC50 of 100 and 2 microM respectively. After exposure of MCF-7 cells to the HA for 24 h, a number of changes were detected in the cells. Growth arrest in the G0/G1 and G2/M phases was observed. The number of cells undergoing early apoptosis and late apoptosis increased. Disruption of the mitochondrial transmembrane potential and disorganization of the inner mitochondrial membrane were induced. Western-blot analysis disclosed that the HA induced apoptosis through the death receptor-mediated pathway.
- Published
- 2010
- Full Text
- View/download PDF
41. Acaconin, a chitinase-like antifungal protein with cytotoxic and anti-HIV-1 reverse transcriptase activities from Acacia confusa seeds.
- Author
-
Lam SK and Ng TB
- Subjects
- Anti-HIV Agents isolation & purification, Anti-HIV Agents metabolism, Antifungal Agents isolation & purification, Antifungal Agents metabolism, Antineoplastic Agents, Phytogenic isolation & purification, Antineoplastic Agents, Phytogenic metabolism, Antineoplastic Agents, Phytogenic pharmacology, Cell Line, Tumor, Cell Survival drug effects, Fusarium drug effects, Helminthosporium drug effects, Hep G2 Cells, Humans, Plant Proteins isolation & purification, Plant Proteins metabolism, Acacia enzymology, Anti-HIV Agents pharmacology, Antifungal Agents pharmacology, Chitinases metabolism, HIV Reverse Transcriptase antagonists & inhibitors, Plant Proteins pharmacology, Seeds chemistry
- Abstract
From the seeds of Acacia confusa, a chitinase-like antifungal protein designated as acaconin that demonstrated antifungal activity toward Rhizoctonia solani with an IC₅₀ of 30±4 µM was isolated. Acaconin demonstrated an N-terminal sequence with pronounced similarity to chitinases and a molecular mass of 32 kDa. It was isolated by chromatography on Q-Sepharose, SP-Sepharose and Superdex 75 and was not bound by either ion exchanger. Acaconin was devoid of chitinase activity. The antifungal activity against Rhizoctonia solani was completely preserved from pH 4 to 10 and from 0°C to 70°C. Congo Red staining at the tips of R. solani hyphae indicated inhibition of fungal growth. However, there was no antifungal activity toward Mycosphaerella arachidicola, Fusarium oxysporum, Helminthosporium maydis, and Valsa mali. Acaconin inhibited proliferation of breast cancer MCF-7 cells with an IC₅₀ of 128±9 µM but did not affect hepatoma HepG2 cells. Its IC₅₀ value toward HIV-1 reverse transcriptase was 10±2.3 µM. The unique features of acaconin include relatively high stability when exposed to changes in ambient pH and temperature, specific antifungal and antitumor actions, potent HIV-reverse transcriptase inhibitory activity, and lack of binding by strongly cationic and anionic exchangers.
- Published
- 2010
42. Isolation and characterization of a lectin with potentially exploitable activities from caper (Capparis spinosa) seeds.
- Author
-
Lam SK, Han QF, and Ng TB
- Subjects
- Amino Acid Sequence, Animals, Antifungal Agents pharmacology, Antineoplastic Agents, Phytogenic pharmacology, Breast Neoplasms drug therapy, Carcinoma, Hepatocellular drug therapy, Cell Line, Tumor, Cell Proliferation drug effects, Concanavalin A pharmacology, Dimerization, Female, Fungi drug effects, HIV Reverse Transcriptase antagonists & inhibitors, Humans, Hydrogen-Ion Concentration, Inhibitory Concentration 50, Liver Neoplasms drug therapy, Mice, Mitosis drug effects, Molecular Sequence Data, Molecular Weight, Mycelium drug effects, Plant Lectins chemistry, Plant Lectins pharmacology, Protein Stability, Spleen cytology, Spleen physiology, Temperature, Capparis chemistry, Plant Lectins isolation & purification, Plant Lectins metabolism, Seeds chemistry, Seeds metabolism
- Abstract
A dimeric 62-kDa lectin exhibiting a novel N-terminal amino acid sequence was purified from caper (Capparis spinosa) seeds. The purification protocol involved anion-exchange chromatography, cation-exchange chromatography and, finally, gel filtration by FPLC on Superdex 75. Approx. 100-fold purification was achieved. The haemagglutinating activity of the lectin, which was stable in the pH range 1-12 and up to 40 degrees C, could be inhibited by D(+) galactose, alpha-lactose, raffinose and rhamnose at 1 mM concentration, by 25 mM L(+)-arabinose and by 100 mM D(+)GlcN (glucosamine). The lectin potently inhibited HIV-1 reverse transcriptase with an IC50 of 0.28 microM and proliferation of both hepatoma HepG2 and breast cancer MCF-7 cells with an IC50 of approx. 2 microM. It induced apoptosis in HepG2 and MCF-7 cells. It manifested a weaker mitogenic activity on mouse splenocytes than ConA (concanavalin A). It inhibited mycelial growth in Valsa mali with an IC50 of 18 microM.
- Published
- 2009
- Full Text
- View/download PDF
43. Novel galactonic acid-binding hexameric lectin from Hibiscus mutabilis seeds with antiproliferative and potent HIV-1 reverse transcriptase inhibitory activities.
- Author
-
Lam SK and Ng TB
- Subjects
- Amino Acid Sequence, Animals, Antineoplastic Agents, Phytogenic pharmacology, Cell Line, Tumor, Chromatography, Gel, Chromatography, Ion Exchange, Hemagglutination drug effects, Hep G2 Cells, Humans, Inhibitory Concentration 50, Plant Lectins chemistry, Plant Lectins pharmacology, Protein Binding, Protein Multimerization, Rats, Reverse Transcriptase Inhibitors pharmacology, Seeds chemistry, Sugar Acids chemistry, HIV Reverse Transcriptase antagonists & inhibitors, Hibiscus chemistry, Plant Lectins isolation & purification
- Abstract
A hexameric 150-kDa lectin was isolated from dried Hibiscus mutabilis seeds using a chromatographic protocol that involved ion exchange chromatography on SP-Sepharose, and gel filtration on Superdex 75 and Superdex 200. The lectin was not adsorbed on SP-Sepharose and was eluted from the Superdex 75 column in the void volume. It was eluted in the first peak from Superdex 200. It was strongly adsorbed on DEAE-cellulose and Q-Sepharose and could not be easily desorbed. The hemagglutinating activity of the lectin, which was stable at pH 4-7 and up to 50 degrees C, could be inhibited by 25 mM galactonic acid. This is the first report of a galactonic acid-binding lectin. It potently inhibited HIV-1 reverse transcriptase with an IC(50) of 0.2 microM. It exhibited weak antiproliferative activity towards both hepatoma HepG2 cells (40% inhibition) and breast cancer MCF-7 cells (50% inhibition) at 100 microM concentration of the lectin. It did not inhibit mycelial growth of a number of fungi tested.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.